Cargando…
CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro
Ovarian cancer (OC) is the most frequent cause of mortality among gynecological malignancies, with a 5-year survival rate of approximately 30%. The standard regimen for OC therapy includes a platinum agent combined with a taxane, to which the patients frequently acquire resistance. Resistance arises...
Autores principales: | ZHU, ZHUANGYAN, MU, YAQIN, QI, CAIXIA, WANG, JIAN, XI, GUOPING, GUO, JUNCHENG, MI, RUORAN, ZHAO, FUXI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292762/ https://www.ncbi.nlm.nih.gov/pubmed/25516145 http://dx.doi.org/10.3892/ijmm.2014.2041 |
Ejemplares similares
-
Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019) -
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007) -
In vitro and in vivo Evaluation of CYP1A Interaction Potential of Terminalia Arjuna Bark
por: Varghese, Alice, et al.
Publicado: (2014) -
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016) -
Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo
por: Yao, Shu, et al.
Publicado: (2018)